Opendata, web and dolomites


Diagnosis test for immuno-oncology therapies.

Total Cost €


EC-Contrib. €






 IMMUNOTRAP project word cloud

Explore the words cloud of the IMMUNOTRAP project. It provides you a very rough idea of what is the project "IMMUNOTRAP" about.

surface    drugs    thanks    inmuno    diagnosis    oncology    genetic    homogeneous    immunotrap    forces    marketing    few    light    physical    physics    workhorse    receptors    cell    cancers    uses    2018    solution    laser    innovation    binding    endpoint    cytometry    mutations    optical    mechanically    entry    assessing    clinical    confirm    suitable    routes    tumors    recognition    company    plasmon    characterization    offers    flow    personalised    performance    measured    fundamental    immunoassays    impetux    precisely    awarded    technique    transfer    until    platform    techniques    opportunity    ground    force    start    screening    heterogeneity    back    affinity    disrupting    successful    nobel    selecting    interaction    samples    boost    unmet    immunotherapies    invention    market    intellectual    commercial    efforts    father    differently    ago    resonance    efficient    pharmaceutical    drifting    contact    industry    prize    tweezers    breaking    generally    act    transferring    immune    interact    patient    therapies    cells    cancer    1980s    exhibit    treatments    create    adoptive   

Project "IMMUNOTRAP" data sheet

The following table provides information about the project.


Organization address
address: CALLE TRIAS I GIRO 15
postcode: 8034
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-09-01   to  2020-02-29


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    IMPETUX OPTICS SL ES (BARCELONA) coordinator 50˙000.00


 Project objective

Cancers exhibit a large heterogeneity in terms of genetic mutations, so they respond differently to the same drugs. This is why oncology is rapidly drifting towards treatments with new disrupting personalised inmuno-oncology therapies based on adoptive T-cell transfer (ACT). These therapies aim at selecting the most efficient T cells against tumors and transferring them back to the patient. This kind of Immunoassays are generally carried out with endpoint measurements like Surface Plasmon Resonance or Flow Cytometry. However, these techniques do not allow assessing the binding process between the immune and the target cell, which represents a fundamental step of the recognition phase where large efforts against cancer focus. IMPETUX has developed a solution to address this unmet need. The characterization of this affinity will be achieved through the measurement of the interaction force between them with IMMUNOTRAP: a platform for cell screening based on IMPETUX‘s optical tweezers. This technology uses a highly-focused laser light to mechanically interact with the sample without physical contact. The recent 2018 Nobel Prize in Physics was awarded to the intellectual father of this technique for his ground-breaking invention in the 1980s. However, it was not until few years ago that forces could start being measured on non-homogeneous samples, such as cells, thanks to the technology developed by IMPETUX. The IMMUNOTRAP has the potential to become the workhorse in the screening of the best performance receptors for their use in immunotherapies and offers IMPETUX the opportunity to address a high-growth potential market: the pharmaceutical industry and clinical diagnosis. It represents, therefore, a key opportunity to boost the company’s growth. Thus, the objectives of the present innovation project is precisely to confirm the potential of the proposal to create value and to identify the most suitable marketing and commercial routes for a successful market entry.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMMUNOTRAP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IMMUNOTRAP" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MCBD (2019)


Read More  

CyreenApplication (2019)

Connecting Ad-Impressions with Purchase. The new advanced Advertisement at the point of sales.

Read More  

EVERCAM (2020)

Intelligent Vision System for Improved Communication and Higher Productivity in Construction

Read More